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Abstract
Background: Reporting of the flow of participants through each stage of a randomized trial is essential to assess
the generalisability and validity of its results. We assessed the type and completeness of information reported in
CONSORT (Consolidated Standards of Reporting Trials) flow diagrams published in current reports of randomized
trials.
Methods: A cross sectional review of all primary reports of randomized trials which included a CONSORT flow
diagram indexed in PubMed core clinical journals (2009). We assessed the proportion of parallel group trial
publications reporting specific items recommended by CONSORT for inclusion in a flow diagram.
Results: Of 469 primary reports of randomized trials, 263 (56%) included a CONSORT flow diagram of which 89%
(237/263) were published in a CONSORT endorsing journal. Reports published in CONSORT endorsing journals were
more likely to include a flow diagram (62%; 237/380 versus 29%; 26/89). Ninety percent (236/263) of reports which
included a flow diagram had a parallel group design, of which 49% (116/236) evaluated drug interventions, 58%
(137/236) were multicentre, and 79% (187/236) compared two study groups, with a median sample size of 213
participants. Eighty-one percent (191/236) reported the overall number of participants assessed for eligibility, 71%
(168/236) the number excluded prior to randomization and 98% (231/236) the overall number randomized.
Reasons for exclusion prior to randomization were more poorly reported. Ninety-four percent (223/236) reported
the number of participants allocated to each arm of the trial. However, only 40% (95/236) reported the number
who actually received the allocated intervention, 67% (158/236) the number lost to follow up in each arm of the
trial, 61% (145/236) whether participants discontinued the intervention during the trial and 54% (128/236) the
number included in the main analysis.
Conclusions: Over half of published reports of randomized trials included a diagram showing the flow of
participants through the trial. However, information was often missing from published flow diagrams, even in
articles published in CONSORT endorsing journals. If important information is not reported it can be difficult and
sometimes impossible to know if the conclusions of that trial are justified by the data presented.
Background
The CONSORT (CONsolidated Standards Of Reporting
Trials) Statement, most recently updated in 2010, is an
evidence-based, minimum set of recommendations for
reporting the findings of randomized trials [1,2] It offers
a standard way for authors to prepare reports of trial
findings, facilitating their complete and transparent
reporting, and aiding their critical appraisal and inter-
pretation. The statement consists of a checklist of items
to be addressed in the text of a report of a randomized
trial, especially the methods and results sections, and a
flow diagram which shows the flow of participants
through each stage of a trial. There is evidence to show
that journal adoption of the CONSORT Statement leads
to improvements in the reporting of randomized trials
[3], aiding their critical assessment by readers.
For some randomized trials the flow of participants
through each phase of the trial can be relatively straight-
forward to describe, particularly where there were no
losses to follow-up or exclusions. However, in more
complex trials it may be difficult for readers to discern
whether and why some participants did not receive the
treatment as allocated, were lost to follow-up, or were
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cial as participants who were excluded after allocation
are unlikely to be representative of all participants in
the study [5]. A completed flow diagram is especially
valuable for such trials.
The template for the CONSORT flow diagram [1,2] is
shown in Figure 1. Information required to complete a
CONSORT flow diagram includes the number of parti-
cipants evaluated for potential enrolment into the trial
(if known) and the number excluded at this stage either
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Assessed for 
eligibility (n = …)
Excluded (n = …)
Not meeting
inclusion criteria
(n = …)
Declined to participate
(n = …)
Other reasons (n = …)
Randomised (n = …)
Lost to follow up (n = …)
(give reasons) 
Discontinued intervention 
(n = …) (give reasons)
Analysed (n = …)
Excluded from analysis
(give reasons) (n = …)
Allocated to intervention 
(n = …)
Received allocated 
intervention  (n = …)
Did not receive allocated
intervention  
(give  reasons) (n = …)
Lost to follow up (n = …)
(give reasons) 
Discontinued intervention 
(n = …) (give reasons)
Allocated to intervention 
(n = …)
Received allocated 
intervention  (n = …)
Did not receive allocated
intervention  
(give  reasons) (n = …)
Analysed (n = …)
Excluded from analysis
(give reasons) (n = …)
Figure 1 Flow diagram of the progress through the phases of a 2-group parallel randomized trial (1;2).
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Page 2 of 10because they did not meet the inclusion criteria or
declined to participate. It also requires for each inter-
vention group the numbers of participants who were
randomly assigned, received treatment as allocated,
completed treatment as allocated, and were included in
the main analysis, with numbers and reasons for exclu-
sions at each step.
If important information is not reported it is often not
possible to tell which participants received which inter-
vention and how they were included in the analysis,
making it difficult or sometimes impossible to know
whether the conclusions of the trial are justified by the
data [6]. A complete CONSORT flow diagram reduces
the time for readers to find the essential information to
assess the reliability of a trial. It is also likely to improve
the availability of some information which otherwise
might not be reported.
The aim of our study was to provide a comprehensive
assessment of the type and completeness of information
reported in CONSORT flow diagrams published in cur-
rent reports of randomized trials. We also examined a
random sample of reports, for which some items were
missing from the CONSORT flow diagram, to see
whether appropriate information was reported elsewhere
in the text and how much time was required to identify
this additional information. We did not examine the
text of reports that did not include a flow diagram.
Methods
Sample
We searched PubMed for all reports of randomized
trials indexed from 1 July to 31 December 2009 with
the publication type “Randomized Controlled Trial”
(search as of 4 January 2010). This search strategy was
chosen based on a review of published search filters for
retrieving reports of randomized trials from MEDLINE,
which found that the publication type term “Rando-
mized Controlled Trial” performed well with 93% sensi-
tivity, 98% specificity and 56% precision [7]. We limited
our search to the National Library of Medicine’ss e to f
core clinical journals (Abridged Index Medicus) as these
journals are typical of those accessed by busy clinicians.
All journals published in this set are in English.
Eligibility criteria
We included all primary reports of a randomized trial
defined as a prospective study assessing health-care
interventions in human participants who were randomly
allocated to study groups. We included all studies of
parallel group, crossover, cluster, factorial and split-body
design. If a publication described more than one report
of a randomized trial, we included the first trial or the
trial including the most information. Interim analysis,
secondary publications, editorials, letters, studies of
cost-effectiveness and diagnostic test accuracy reports
were excluded.
Review progress
One person (SH) screened the titles and abstracts of all
retrieved reports to exclude any obvious ineligible stu-
dies (i.e. not trials). A copy of the full report was then
assessed for all remaining articles. Any additional mate-
rial about the trial included as an appendix on the jour-
nal website was also obtained, if available. All reports
were then classified as either including a CONSORT
flow diagram [1,2] (eligible) or not including a CON-
SORT flow diagram (ineligible).
Data extraction
Data extraction was carried out by five reviewers work-
ing in pairs (in blocks of 50 articles allocated at ran-
dom). Each pair independently extracted data from
eligible reports; any differences between reviewers were
resolved by discussion with the involvement of an arbi-
trator if necessary. To ensure consistency between
reviewers, they all piloted the data extraction form using
a sample of 10 papers from the sample under review. A
data extraction manual was developed to provide gui-
dance for each item on the data extraction form.
For each eligible report we extracted information on
the trial design, journal type, medical specialty, type of
intervention, number of data collection sites, number of
randomized groups, sample size and whether the report
was published in a CONSORT endorsing journal based
on the journals’‘ Instructions to Authors’ (assessed
November 2010).
We extracted from the flow diagram whether informa-
tion (either directly reported or could be inferred from
the flow diagram) was provided on the number of
participants:
￿ assessed for eligibility (overall), excluded as they did
not meet the inclusion criteria, excluded as they met
inclusion criteria but declined to participate, or excluded
for other reasons;
￿ randomized (overall);
￿ allocated to intervention (per group), received the
allocated intervention (per group), did not receive the
allocated intervention (per group), and reasons they did
not receive the allocated intervention (per group);
￿ lost to follow-up (per group), reasons for lost to fol-
low up (per group), discontinued intervention (per
group), and reasons for discontinued intervention (per
group);
￿ included in main analysis (per group), excluded from
analysis (per group), and reasons excluded from analysis
(per group);
We also extracted data on any additional information
included in the flow diagram (overall or per group).
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which had items missing or flagged as unclear) we
examined a random sample (25%; n = 54) of reports to
see whether the missing information was reported else-
where in the text instead. We also assessed how long it
took to identify this additional information, if reported.
Data analysis
The primary analysis was focused on parallel group
trials; two group and multi-arm. We calculated the pro-
portion (%) of parallel group trial publications reporting
specific items included in the CONSORT flow diagram.
We also carried out an analysis on the reporting of clus-
ter trials which included a participant flow diagram
based on the guidance in the CONSORT extension for
cluster trials [8].
Results
The PubMed publication type search term “Randomized
Controlled Trial” identified 644 possible reports of ran-
domized trials. After screening the titles and abstracts of
all retrieved citations, we reviewed 541 full text articles
resulting in 469 primary reports of randomized trials
(Figure 2); of these 380 were published in journals
which referred to the CONSORT Statement in their
journal’s Instruction to Authors and 89 were published
in journals which did not refer to CONSORT. Sixty-two
percent (237/380) of reports published in a CONSORT
endorsing journal included a CONSORT flow diagram
compared to only 29% (26/89) of reports published in a
non CONSORT endorsing journal.
Thus, 263 (56%) of the 469 primary reports of rando-
mized trials included a CONSORT flow diagram; 236/
263 (90%) were reports of parallel group trials, 16 (6%)
were cluster randomized, four (1.5%) were crossover,
four (1.5%) were factorial and three (1%) were split body
trials (Figure 2). The primary trial reports were pub-
lished in 50 different journals, with the majority appear-
ing in specialty journals. The journals with the most
reports in the sample were the Lancet (n = 27), New
England Journal of Medicine (n = 23), BMJ (n = 20),
JAMA (n = 18) and Pediatrics (n = 16). Ninety percent
(237/263) of articles included in our cohort were pub-
lished in journals which referred to the CONSORT
Statement in their journal’s Instruction to Authors; 41/
50 (82%) journals. In comparison 69% (143/206) of arti-
cles which did not include a flow diagram, thus
excluded from our analysis, were published in journals
which referred CONSORT Statement in their journal’s
Instruction to Authors; 25/55 (45%) journals.
Table 1 provides information on reporting of general
trial characteristics. Around half (49%; n = 116) of paral-
lel group trials investigated drugs as the primary inter-
vention of interest, 20% (n = 46) assessed surgical or
procedural interventions, 27% (n = 64) assessed counsel-
ling or lifestyle interventions and the remaining 4% (n =
10) assessed equipment/devices. Thirty-one percent (n =
72) of parallel group trial reports explicitly stated that
they were single centre trials and 58% (n = 137) stated
that they were multicentre; the number of study centres
was not explicitly defined in the remaining reports (n =
27). The majority of parallel group trials (79%; n = 187)
had two study arms. The median number of participants
recruited per parallel group trial was 213 (10
th to 90
th
percentile 50 to 1217); this was smaller than for the
group “other” trials (median 529; 10
th to 90
th percentile
56 to 61280) due to the inclusion of cluster randomized
trials.
Sources of funding were provided in most trial
reports; 17% (n = 40) of parallel group trials were
funded solely by industry, 18% (n = 43) were part indus-
try funded and 53% (n = 126) were non industry funded.
For comparison, information on reporting of general
trial characteristics for non parallel group trials is also
provided in Table 1.
Information included in CONSORT flow diagrams for
parallel group trials
Table 2 provides a summary of the information reported
(either directly reported or could be inferred from the
flow diagram) in the CONSORT flow diagram for the
236 reports of parallel group trials which included a par-
ticipant flow diagram. Eighty-one-percent (n = 191) of
flow diagrams reported the overall number of people
assessed for eligibility, 71% (n = 168) reported the over-
all number of people excluded prior to randomization
and 98% (n = 231) reported the overall number rando-
mized. Reasons for exclusion prior to randomization
were less well reported; only 57% (n = 136) reported the
number of people excluded because they did not meet
the inclusion criteria for the trial, 66% (n = 157)
reported the number excluded because they declined to
participate in the trial and 60% (n = 141) reported the
number excluded for other reasons.
The majority (94%; n = 223) of flow diagrams reported
the number of participants allocated to each arm of the
trial, however less than half (40%; n = 95) reported the
number of participants in each arm of the trial who
actually received the allocated intervention. Just over a
third (38%; n = 91) of flow diagrams reported the num-
ber of participants who did not receive the allocated
intervention; only 32% (n = 76) gave the reason for
exclusion, for example, withdrawal of patient consent or
change in initial patient diagnosis. Sixty-seven percent
(n = 158) of flow diagrams included the numbers lost to
follow up in each arm of the trial; under half (40%; n =
93) reported the reason for loss to follow up for exam-
ple the patient had moved and could not be located.
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many participants discontinued the intervention during
the trial; 54% (n = 128) reported the reason for disconti-
nuation for example death of the patient, adverse effects
of the intervention or for personal reasons. Just over
half (54%; n = 128) of flow diagrams reported the num-
ber of participants included in the analysis and few
(35%; n = 82) explicitly stated the number excluded
644 PubMed citations
103 excluded:
45 secondary publications
36 non-randomized studies
5 economic evaluation studies
5 phase I and II studies
3 reviews
3 study protocols
2 diagnostic test studies
2 interim analysis reports
2 non-human studies
72 excluded:
49 secondary publications
9 non-randomized studies
7 editorial/letters
5 study protocols
1 diagnostic test study
1 methodology study
541 full articles reviewed
469 randomized trials
206 flow diagram not reported
263 flow diagram 
included
236 parallel group
randomized trials
16 cluster randomized trials
4 crossover randomized trials
4 factorial randomized trials
3 split body randomized trials
Figure 2 Identification of randomized trials from PubMed citations indexed from July to December 2009.
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Page 5 of 10from the analysis; or the reason for exclusion from the
analysis (33%; n = 78).
In addition to the information currently required to
complete a CONSORT flow diagram we also assessed
any additional information that was included. Among
the 236 flow diagrams, 10 (4%) reported the overall
number of participants screened prior to eligibility
assessment, 20 (8%) reported the number of participants
lost to follow up in each arm of the trial for more than
one time point and four (2%) reported the number of
participants in each arm of the trial included in both an
intention to treat and per protocol analysis. We also
noted some instances where the number of participants
didn’t add up across the flow diagram; however we
didn’t assess this systematically across all trials. Interest-
ingly, despite approximately half of trial reports asses-
sing non drug interventions (Table 1), no flow diagram
reported the number of care providers or centres per-
forming the intervention or the number of patients trea-
ted by each care provider or in each centres - as
recommended in the CONSORT extension for non-
pharmacological interventions [9].
While Table 2 provides a summary of the number and
proportion of trials explicitly reporting different CON-
SORT flow diagrams items, there were many instances
where an item was either missing from the flow diagram
or where the information reported for that item was
unclear. A good example of the latter is that authors
sometimes combined reporting of loss to follow and dis-
continuation of the treatment intervention and did not
differentiate between them. Similarly, authors sometimes
combined the reasons for exclusion prior to randomiza-
tion and so the exact reasons for exclusions (e.g. not
meeting inclusion criteria, declined to participate) were
unclear.
Information included in CONSORT flow diagrams for
cluster randomized trials
Table 3 provides a summary of the information reported
in the CONSORT flow diagram for the subset of 16
cluster trials that included a participant flow diagram.
Guidance in the CONSORT extension for presenting
cluster trials [8] suggests that the information in the dia-
gram might vary depending on the type of analysis. We
assessed for each item whether the flow diagram
reported the number of clusters, the number (e.g. total,
median or mean) of participants or both. There was
considerable variability in the type and level of detail
reported.
Reporting of additional information in the text of the full
publication in parallel group trials
Only 18 of the 236 flow diagrams had complete infor-
mation. In the final part of the study we sought to iden-
tify whether information not reported in the flow
diagram was reported in the text of the full publication
and if so, how long it took to locate. Across the 236
reports of parallel group trials the median number of
items either not reported or flagged as unclear based on
the information in the flow diagram was seven out of a
possible 17 items (IQR 4 to 10); 41% (IQR 24% to 59%).
Table 1 General characteristics of randomized trials
reporting a flow diagram indexed in PubMed from July
to December 2009 (n = 263)
Trial design Parallel
(n = 236)
Other *
(n = 27)
Journal type
Specialty 144 (61%) 11 (41%)
General medical 92 (39%) 16 (59%
Funding
Solely industry 40 (17%) 1 (4%)
Part industry 43 (18%) 2 (7%)
Non industry 126 (53%) 20 (74%)
None 5 (2%) 2 (7%)
Unknown 22 (9%) 2 (7%)
CONSORT endorsing journal
Yes 210 (89%) 27 (100%)
No 26 (11%) 0 (0%)
Top 5 common specialty fields
Paediatrics 34 (14%) Paediatrics 10 (34%)
Cardiology 29 (12%) Cardiology 2 (7%)
Psychiatry 20 (9%) Psychiatry 2 (7%)
Infectious diseases 20
(9%)
Infectious diseases 2
(7%)
Oncology 17 (7%) Oncology 1 (3%)
Intervention
Drug 116 (49%) 6 (22%)
Surgery/procedure 46 (20%) 3 (11%)
Counselling/
lifestyle
64 (27%) 15 (56%)
Equipment 10 (4%) 3 (11%)
Study centres
Single 72 (31%) 4 (15%)
Multiple 137 (58%) 20 (74%)
Unclear 27 (11%) 3 (11%)
Number of study groups
2 187 (79%) 20 (74%)
3 36 (15%) 2 (7%)
4 11 (5%) 3 (11%)
> 4 2 (1%) 2 (7%)
Sample size
Median (IQR) 213 (101 to 476) 529 (130 to 2243) †
10 to 90
percentile
50 to 1217 56 to 61280
* Cluster n = 16; Crossover n = 4; Factorial n = 4; Split Body n = 3
† Sample size not reported for 1 cluster trial
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Page 6 of 10Table 2 Reporting of CONSORT flow diagram items for parallel group trials (n = 236)
Reported * Not reported Unclear
Enrolment
Assessed for eligibility (overall) 191 (81%) 43 (18%) 2 (1%)
Excluded (overall) 168 (71%) 64 (27%) 4 (2%)
Not meeting inclusion criteria 136 (57%) 54 (23%) 46 (20%)
Declined to participate 157 (66%) 56 (24%) 23 (10%)
Other reasons 141 (60%) 55 (23%) 40 (17%)
Randomized (overall) 231 (98%) 2 (1%) 3 (1%)
Allocation
Allocated to intervention (per group) 223 (94%) 7 (3%) 6 (3%)
Received allocated intervention (per group) 95 (40%) 120 (51%) 21 (9%)
Did not receive allocated intervention (per group) 91 (38%) 117 (50%) 28 (12%)
Reported reasons did not receive intervention 76 (32%) 133 (55%) 27 (11%)
Follow up
Lost to follow up (per group) 158 (67%) 47 (20%) 31 (13%)
Reported reasons lost to follow up 93 (40%) 116 (49%) 27 (11%)
Discontinued intervention (per group) 145 (61%) 46 (20%) 45 (19%)
Reported reasons discontinued intervention 128 (54%) 65 (28%) 42 (18%)
Analysis
Included in main analysis (per group) 128 (54%) 108 (46%)
Excluded from main analysis (per group) 82 (35%) 154 (65%)
Reported reasons excluded 78 (33%) 128 (67%)
* Directly reported or could be inferred from the flow diagram.
Table 3 Reporting of CONSORT flow diagram items for cluster trials (n = 16)
Reported * Cluster level Patient level ≠ Not applicable
Enrolment
Assessed for eligibility (overall) 12 (75%) 8/12 4/12
Excluded (overall) 11 (69%) 7/11 4/11 1/11
Not meeting inclusion criteria 8 (50%) 2/8 5/8 1/8
Declined to participate 11 (69%) 3/11 2/11 6/11
Other reasons 10 (63%) 4/10 3/10 4/10
Randomized (overall) 15 (94%) 13/15 4/15
Allocation
Allocated to intervention (per group) 15 (94%) 14/15 8/15
Received allocated intervention (per group) 14 (88%) 8/14 14/14
Did not receive allocated intervention (per group) 14 (88%) 6/14 10/14
Reported reasons did not receive intervention 12 (75%) 4/12 9/12
Follow up
Lost to follow up (per group) 13 (81%) 6/13 12/13
Reported reasons lost to follow up 11 (69%) 3/11 9/11
Discontinued intervention (per group) 10 (63%) 2/10 3/10 6/10
Reported reasons discontinued intervention 10 (63%) 1/10 3/10 6/10
Analysis
Included in main analysis (per group) 15 (94%) 9/15 14/15
Excluded from main analysis (per group) 12 (75%) 2/12 7/12 4/12
Reported reasons excluded 12 (75%) 1/12 7/12 4/12
* Directly reported or could be inferred from the flow diagram.
≠Patient level: 10 flow diagrams reported the total number of participants, 2 reported the median and range, 1 reported the mean and total number of
participants, 1 reported the mean and standard deviation, 1 reported the average and range and 1 reported the median, range and total number of participants.
Some flow diagrams reported both the number of clusters per item and the number of participants.
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where information was either not reported or unclear in
the flow diagram to see if it was available elsewhere in
the text or in tables or figures. Based only on the infor-
mation reported in the 54 flow diagrams the median
number of items either not reported or unclear was
seven (IQR 3 to 11); 41% (IQR 18% to 65%). Informa-
tion retrieved from the full text reduced the number of
items which were either missing or unclearly reported
to a median of four items per flow diagram (IQR 1 to
6); 24% (IQR 6% to 35%). Improvement generally
focused on the clarification of reasons for exclusion and
the numbers of participants included and excluded from
the analysis (Table 4). Of particular interest, while only
half (50%; n = 27/52) of flow diagrams provided infor-
mation on the number of participants included in the
main analysis this increased to 94% (n = 51/54) when
examining the full text and relevant tables and figures.
However, it required more time on the part of the
reader to extract this information. Overall the median
time required to extract additional information from the
full article was six minutes (IQR 4 to 10), although
there was some variation depending on the expertise of
the reviewer.
Discussion
Principle findings of study
Our study provides a comprehensive assessment of
the type and completeness of information reported in
CONSORT flow diagrams published in current
reports of randomized trials. Just over half (56%) of
reports of randomized trials in our sample included a
CONSORT flow diagram. This uptake might partly
reflect the criteria for including journals in the
National Library of Medicine core clinical journal list,
and partly the large number of journals (79%)
included in our sample which referred to the CON-
SORT Statement in their ‘Instructions to Authors’.
Indeed, one could argue that the number of reports of
randomized trials including a flow diagram should be
higher if those journals, which endorsed the CON-
SORT Statement, made inclusion of a flow diagram a
requirement to journal submission. However, as has
been shown previously, the language used in such
endorsements varies markedly from requirement to
mild encouragement [10].
The majority of reports of randomized trials which
included a flow diagram were two-arm, parallel group
trials investigating drugs as the primary intervention of
interest. The average sample size was larger than that
identified in a previous study conducted by our team
which examined the reporting characteristics of rando-
mized trials indexed in PubMed in 2006 [11], there the
median sample size for parallel group trials was 80 ver-
sus 213 in our current study. That difference may well
be a reflection of the journals tending to be more presti-
gious and higher impact than the full PubMed sample in
the previous study.
Table 4 Additional information reported in the text of the full publication for parallel group trials (n = 54)
Reported * in flow diagram only Reported * in flow
diagram or text
Enrolment
Assessed for eligibility (overall) 43 (80%) 44 (81%)
Excluded (overall) 40 (74%) 45 (83%)
Not meeting inclusion criteria 28 (52%) 37 (68%)
Declined to participate 34 (63%) 39 (72%)
Other reasons 29 (54%) 39 (72%)
Randomized (overall) 51 (94%) 52 (96%)
Allocation
Allocated to intervention (per group) 49 (91%) 52 (96%)
Received allocated intervention (per group) 22 (41%) 33 (61%)
Did not receive allocated intervention (per group) 19 (35%) 29 (54%)
Reported reasons did not receive intervention 17 (31%) 28 (52%)
Follow up
Lost to follow up (per group) 37 (68%) 43 (80%)
Reported reasons lost to follow up 22 (41%) 29 (54%)
Discontinued intervention (per group) 34 (63%) 38 (70%)
Reported reasons discontinued intervention 30 (55%) 37 (68%)
Analysis
Included in main analysis (per group) 27 (50%) 51 (94%)
Excluded from main analysis (per group) 20 (37%) 48 (89%)
Reported reasons excluded 18 (33%) 42 (77%)
* Directly reported or could be inferred from the flow diagram.
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reported across trials; most published flow diagrams
included the overall number of people assessed for elig-
ibility, the overall number randomized, and the number
allocated to the intervention per arm. However, only
40% of flow diagrams reported the number of partici-
pants (per arm) who actually received the intervention,
and only 54% reported the number included in the main
analysis. Details of the number of participants lost to
follow up or discontinuing the intervention were also
less well reported and authors sometimes combined
these two items and did not differentiate between them.
Some additional information was reported in the text,
most often the reasons for exclusion and the numbers
of participants included and excluded from the analysis,
but this additional information did not greatly alter our
findings and locating it required additional time and
effort for the reader.
Comparison with other studies
Several studies have looked at how often reports of
randomized trials include a participant flow diagram
and the type of information reported [4,12-16]. How-
ever, these studies are now out of date and have gener-
ally been restricted to trials in specific disease areas,
journal types, or looked at specific elements of the
flow of participants through the trial. A study of 207
randomized trials published in five general and internal
medical journals in 1998 found that 51% of reports
included a flow diagram; but this varied widely across
journals [4]. Another study of randomized trials pub-
lished in 1999 found that flow diagrams were more
frequent in the Lancet (95%) and JAMA (86%) com-
pared to the New England Journal of Medicine (13%)
and BMJ (28%) [14].
One study looked specifically at the reporting of the
recruitment process in 172 reports of randomized trials
published in four high impact medical journals in 1999
to 2000. This found that 52% of flow diagrams reported
the number of participants assessed for eligibility and
only 43% reported the number eligible for participation
in the trial [12]. In a more recent study of 113 reports
of randomized trials published in six major journals in
2004, 79% of reports included a flow diagram, but over
a third were incomplete. While the majority of flow dia-
grams reported the flow of participants at each stage of
the trial after randomization, only 60% reported the
number of participants assessed for eligibility [15].
Another study looking specifically at reports of rando-
mized trials (n = 58), in the field of nutrition in preg-
nancy, found that while the majority (97%) of studies
reported the number of participants allocated to each
arm of the trial, only a third (31%) reported the number
of participants assessed for eligibility [13].
These studies all show variability in the completeness
and type of information reported and variation in their
findings may primarily reflect changes over time and
where the reports were published, with the majority of
studies assessing a select group of high impact journals.
Perhaps what is most interesting, when comparing the
results of previous studies with those from our study, is
the difference in reporting of the number of participants
assessed for eligibility. Poor reporting of participant elig-
ibility makes it difficult to know whether the enrolment
process was highly selective and whether those who
enrolled were representative of the general population
[16,17]. Information on the overall number of partici-
pants assessed for eligibility has been poorly reported in
previous studies but was reported in around 81% of flow
diagrams included in our study. This could be an indica-
tion that trialists are now more likely to collect this level
of detailed information as more journals ask authors to
comply with the CONSORT Statement [10].
Limitations of study
Our study has some limitations. We assessed only
reports of trials which included a flow diagram. What
we don’t know is whether, in those trial reports which
did not include a flow diagram, this type of information
is available in the text and tables nor how long it would
take a reader to locate this information; this will be sub-
j e c tt oaf u t u r es t u d y .W el i m i t e do u rs e a r c ht ot h e
National Library of Medicine’s set of core clinical jour-
nals as these journals are typical of those accessed by
most busy clinicians. This sample included a high pro-
portion of journals which endorsed the CONSORT
Statement which therefore should have included a
CONSORT flow diagram. Therefore our findings might
not be representative of all published reports of trials.
We also recognise that there was a time lapse between
publication of the trial reports in 2009 and when the
journal ‘Instruction to Authors’ were assessed (Novem-
ber 2010). It is possible that a journal’s endorsement of
the CONSORT Statement may have changed during
this time period; however, this is likely to be the case
for very few trial reports and as such unlikely to signifi-
cantly affect our conclusions
Implications for practice
It is clear that although a substantial number of pub-
lished trials now include a CONSORT flow diagram
these are not always completed adequately. Endorse-
m e n to ft h eC O N S O R TS t a t e m e n tb yaj o u r n a li sn o t
sufficient, nor is the requirement that authors submit a
flow diagram as part of their manuscript submission if it
is not completed correctly. So what can be done to
assist authors and journal editors? The recently revised
CONSORT explanation and elaboration document is
Hopewell et al. Trials 2011, 12:253
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mination of the CONSORT Statement; however it pro-
vides limited guidance in relation to the flow diagram
[2], with the structure of the flow diagram last being
revised in 2001 [4]. Improved clarification in the struc-
ture of the flow diagram, for example differentiating
more clearly between loss to follow up and discontinua-
tion of the intervention, would make it more logical for
authors to complete and understand the importance of
each item. For more complex trial designs one should
also consider the benefits of including additional infor-
mation in the flow diagram, such as the screening of
participants prior to eligibility assessment, details of
numbers followed up over multiple time points, or num-
bers included in different analyses, all of which were
included in some flow diagrams in our study. In addi-
tion, development of a web based CONSORT flow dia-
gram generator which automates the process of
completing a flow diagram would help authors to com-
plete all sections of the flow diagram appropriately (for
example, https://depts.washington.edu/hrtk/CSD). This
web based tool could be expanded to include both par-
allel group and multi-arms trials and also to take into
account different study designs such as cluster or cross-
over trials.
Conclusions
Clear and detailed reporting of the flow of participants
through each stage of the trial is essential in order to
assess the validity and generalisability of the trial find-
ings. Our study shows that, despite the majority of the
trials included in our sample being published in a CON-
SORT endorsing journal, around 40% of reports of ran-
domized trial did not include a flow diagram. Published
flow diagrams often omitted some key aspects of the
flow of participants through the trial, especially in rela-
tion to reasons for exclusion prior to randomization
and, post randomization, reporting of the number of
participants who actually received the allocated inter-
vention, were lost to follow up or discontinued the
intervention and those included in the main analysis.
About half of these missing items were not available
elsewhere in the article. If important information is not
reported it can be difficult and sometimes impossible to
know if the conclusions of that trial are justified by the
data presented.
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